BMC pulmonary medicine
June 25, 2026
1 min readIP Score 10/10
Hemodynamic improvement but worsening hypoxemia after balloon pulmonary angioplasty: severe eosinophilic asthma unmasked in CTEPH.
Fujii H; Isobe S; Tamura Y
Abstract
We report a patient with peripheral-type chronic thromboembolic pulmonary hypertension (CTEPH) in whom exertional hypoxemia and dyspnea worsened despite substantial hemodynamic improvement after repeated balloon pulmonary angioplasty (BPA), prompting reassessment for a competing ventilatory limitation. Optimization of concomitant severe eosinophilic asthma with benralizumab, an anti-interleukin-5 receptor α monoclonal antibody, and sinus surgery improved airflow obstruction and oxygenation and was accompanied over time by a further reduction in pulmonary arterial pressure. These changes suggest that a superimposed hypoxia-related pulmonary vascular component, compatible with group 3 physiology, may have been attenuated.
This case highlights the diagnostic and management challenges of refractory multisystem sarcoidosis progressing over a two-year period despite advanced biologic therapy.
Clinicians should note that the presence of targetable mutations in non-small cell lung cancer with malignant pleural disease is not associated with improved survival, based on the findings from this study.
Shape-sensing robotic-assisted bronchoscopy achieved a strict diagnostic yield of 70.2% with a low pneumothorax rate of 3.3%, demonstrating that earlier tissue diagnosis of very small pulmonary nodules is feasible and safe for clinical practice.
Up nextJournal of Thoracic DiseaseOct 30, 2026Read
This study introduces ultrasound-guided trans-cannula cryobiopsy of supraclavicular lymph nodes as a novel superficial lymph node approach for tissue acquisition in 10 consecutive patients, though specific numeric success or safety results were not provided in the abstract.
Active infection is not an absolute contraindication to endobronchial valve placement, but positive pressure ventilation significantly increases clinical failure odds with an aOR of 3.00 at P < 0.001.